Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$24.73 +3.9%	$23.35	$20.39 ▼ $53.96	$1.15B	0.76	560,315 shs	18,433 shs
ARDX Ardelyx	$5.20 -0.1%	$4.16	$3.21 ▼ $7.18	$1.25B	0.68	4.79 million shs	5,906 shs
HRTX Heron Therapeutics	$1.39 -24.6%	$2.00	$1.04 ▼ $2.68	$201.38M	1.15	1.64 million shs	14.95 million shs
PRAX Praxis Precision Medicines	$46.83 -0.9%	$48.11	$26.70 ▼ $91.83	$967.04M	2.62	550,888 shs	438,540 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	0.00%	+12.26%	+9.93%	-2.18%	-44.43%
ARDX Ardelyx	0.00%	+20.32%	+16.04%	+47.59%	-8.60%
HRTX Heron Therapeutics	0.00%	-21.89%	-39.45%	-35.61%	-33.33%
PRAX Praxis Precision Medicines	0.00%	-15.07%	-9.10%	+19.57%	-9.57%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMPH Amphastar Pharmaceuticals	4.3054 of 5 stars	3.1	2.0	3.7	2.4	4.2	1.3
ARDX Ardelyx	4.3414 of 5 stars	3.5	2.0	4.4	3.7	2.5	0.6
HRTX Heron Therapeutics	3.7837 of 5 stars	3.5	1.0	4.2	2.3	1.7	0.6
PRAX Praxis Precision Medicines	1.6225 of 5 stars	3.4	1.0	0.0	2.4	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMPH Amphastar Pharmaceuticals	2.25	Hold	$30.00	21.31% Upside
ARDX Ardelyx	3.00	Buy	$11.50	120.98% Upside
HRTX Heron Therapeutics	3.00	Buy	$4.50	224.44% Upside
PRAX Praxis Precision Medicines	2.78	Moderate Buy	$95.22	103.34% Upside

Current Analyst Ratings Breakdown

Latest HRTX, ARDX, PRAX, and AMPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	AMPH Amphastar Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$30.00 ➝ $25.00
8/8/2025	HRTX Heron Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.00
8/6/2025	ARDX Ardelyx	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$8.00 ➝ $9.00
8/5/2025	ARDX Ardelyx	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$12.00
8/5/2025	ARDX Ardelyx	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00 ➝ $12.00
8/5/2025	ARDX Ardelyx	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$13.00 ➝ $14.00
8/5/2025	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$105.00 ➝ $115.00
7/29/2025	PRAX Praxis Precision Medicines	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
7/18/2025	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$105.00
7/8/2025	PRAX Praxis Precision Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$97.00 ➝ $115.00
6/18/2025	ARDX Ardelyx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00

(Data available from 8/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMPH Amphastar Pharmaceuticals	$731.97M	1.57	$5.20 per share	4.76	$15.23 per share	1.62
ARDX Ardelyx	$333.61M	3.76	N/A	N/A	$0.73 per share	7.13
HRTX Heron Therapeutics	$148.52M	1.42	N/A	N/A	($0.22) per share	-6.30
PRAX Praxis Precision Medicines	$8.55M	115.29	N/A	N/A	$23.90 per share	1.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMPH Amphastar Pharmaceuticals	$159.52M	$2.67	9.26	7.52	N/A	18.64%	20.76%	9.68%	N/A
ARDX Ardelyx	-$39.14M	-$0.23	N/A	16.79	N/A	-14.60%	-36.57%	-13.42%	10/30/2025 (Estimated)
HRTX Heron Therapeutics	-$13.58M	-$0.02	N/A	N/A	N/A	-0.62%	N/A	-0.40%	8/11/2025 (Estimated)
PRAX Praxis Precision Medicines	-$182.82M	-$12.29	N/A	N/A	N/A	-2,137.48%	-60.07%	-54.84%	N/A

Latest HRTX, ARDX, PRAX, and AMPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025 & Study Result	PRAX Praxis Precision Medicines	-$3.40	N/A	N/A	N/A	$0.16 million	N/A
8/8/2025	Q2 2025	HRTX Heron Therapeutics	-$0.01	-$0.02	-$0.01	-$0.02	$38.08 million	$37.20 million
8/4/2025	Q2 2025	ARDX Ardelyx	-$0.13	-$0.08	+$0.05	-$0.08	$82.69 million	$97.66 million
8/4/2025	Q2 2025 & Study Result	PRAX Praxis Precision Medicines	-$3.40	-$3.31	+$0.09	-$3.31	$0.15 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMPH Amphastar Pharmaceuticals	0.80	3.29	2.21
ARDX Ardelyx	1.44	4.30	4.03
HRTX Heron Therapeutics	N/A	2.40	1.76
PRAX Praxis Precision Medicines	N/A	6.31	6.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMPH Amphastar Pharmaceuticals	65.09%
ARDX Ardelyx	58.92%
HRTX Heron Therapeutics	80.01%
PRAX Praxis Precision Medicines	67.84%

Insider Ownership

Company	Insider Ownership
AMPH Amphastar Pharmaceuticals	27.10%
ARDX Ardelyx	4.80%
HRTX Heron Therapeutics	5.86%
PRAX Praxis Precision Medicines	2.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMPH Amphastar Pharmaceuticals	2,028	46.49 million	33.90 million	Optionable
ARDX Ardelyx	90	240.98 million	229.42 million	Optionable
HRTX Heron Therapeutics	300	152.56 million	143.62 million	Optionable
PRAX Praxis Precision Medicines	110	21.05 million	20.48 million	Optionable

HRTX, ARDX, PRAX, and AMPH Headlines

Recent News About These Companies

Chardan Capital Brokers Lower Earnings Estimates for PRAX

August 11 at 2:50 AM | marketbeat.com

Praxis Precision Medicines (PRAX) Projected to Post Quarterly Earnings on Tuesday

August 11 at 2:51 AM | americanbankingnews.com

XTX Topco Ltd Purchases Shares of 10,043 Praxis Precision Medicines, Inc. (NASDAQ:PRAX)

August 10 at 3:41 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX

August 9 at 11:33 AM | globenewswire.com

HC Wainwright Issues Optimistic Estimate for PRAX Earnings

August 9 at 2:37 AM | americanbankingnews.com

Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine

August 8 at 10:14 PM | theglobeandmail.com

Research Analysts Issue Forecasts for PRAX Q3 Earnings

August 8 at 8:25 AM | marketbeat.com

What is HC Wainwright's Estimate for PRAX FY2029 Earnings?

August 7, 2025 | marketbeat.com

Wedbush Issues Negative Estimate for PRAX Earnings

August 7, 2025 | marketbeat.com

Wedbush Has Negative Outlook for PRAX Q3 Earnings

August 7, 2025 | americanbankingnews.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX

August 6, 2025 | prnewswire.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Praxis Precision Medicines (PRAX) and Pfizer (PFE)

August 6, 2025 | theglobeandmail.com

Praxis Precision Medicines (NASDAQ:PRAX) Shares Down 8.1% - Here's Why

August 6, 2025 | marketbeat.com

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 6, 2025 | gurufocus.com

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 6, 2025 | globenewswire.com

Praxis Precision Medicines (PRAX) Projected to Post Earnings on Tuesday

August 6, 2025 | marketbeat.com

HC Wainwright Forecasts Strong Price Appreciation for Praxis Precision Medicines (NASDAQ:PRAX) Stock

August 6, 2025 | marketbeat.com

Praxis Precision Medicines First Half 2025 Earnings: US$6.60 loss per share (vs US$4.58 loss in 1H 2024)

August 5, 2025 | finance.yahoo.com

Praxis’ Seizure Drug Demonstrates ‘Impressive’ Efficacy in Mid-Stage Trial

August 5, 2025 | biospace.comB

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

August 5, 2025 | globenewswire.com

Praxis Precision Medicines, Inc. Investors: Company Investigated by the Portnoy Law Firm

August 5, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRTX, ARDX, PRAX, and AMPH Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

$24.73 +0.92 (+3.87%)

As of 09:30 AM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Ardelyx NASDAQ:ARDX

$5.20 -0.01 (-0.12%)

As of 09:30 AM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Heron Therapeutics NASDAQ:HRTX

$1.39 -0.45 (-24.62%)

As of 09:30 AM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Praxis Precision Medicines NASDAQ:PRAX

$46.83 -0.44 (-0.94%)

As of 09:30 AM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time